Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Ixazomib + Rituximab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Ixazomib||Ninlaro||MLN9708||Ninlaro (ixazomib) inhibits proteosome activity, resulting in accumulation of misfolded proteins, inhibition of pathway signaling, and potentially leading to cell death (PMID: 20160034). Ninlaro (ixazomib) in combination with Revlimid (lenalidomide) and dexamethasone is FDA approved for use in patients with multiple myeloma who have received at least one prior therapy (FDA.gov)|
|Rituximab||Rituxan||IDEC-C2B8|MabThera||CD20 Antibody 12||Rituxan (rituximab) is a chimeric mononclonal antibody that binds to CD20 on B-cells, resulting in induction of complement-dependent and antibody-dependent cytotoxicity, and potentially leading to decreased B-cell tumor growth (PMID: 28983798). Rituxan (rituximab) is FDA approved for use as monotherapy or in combination with chemotherapy in CD20-positive B-cell non-Hodgkin lymphoma, and in combination with fludarabine and cyclophosphamide in CD20-positive chronic lymphocytic leukemia (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02339922||Phase II||Ixazomib + Rituximab||Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma||Active, not recruiting||USA||0|
|NCT02632396||Phase Ib/II||Ixazomib + Rituximab||Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission||Active, not recruiting||USA||0|
|NCT04047797||Phase II||Ixazomib + Rituximab||Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma||Recruiting||USA||0|